EcoDrugPlus

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSACLG00000025432
Gene Symbol: ROCK2
3 Cross references
216 Possible Orthologues:

Sem1 26s Proteasome Complex Subunit

Ensembl ID : ENSACLG00000024578
Gene Symbol: SEM1
3 Cross references
156 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSACLG00000021545
Gene Symbol: SRC
4 Cross references
191 Possible Orthologues:

Tgf-Beta Receptor Type-1-Like

Ensembl ID : ENSACLG00000005755
Gene Symbol: LOC113028987
3 Cross references
205 Possible Orthologues:

Ttk Protein Kinase

Ensembl ID : ENSACLG00000024066
Gene Symbol: TTK
3 Cross references
204 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSACLG00000008870
Gene Symbol: UGCG
3 Cross references
212 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSACLG00000022056
Gene Symbol: WEE1
3 Cross references
206 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSACLG00000001229
Gene Symbol: YES1
4 Cross references
197 Possible Orthologues:

Acetylcholinesterase

Ensembl ID : ENSACLG00000015596
Gene Symbol: ACHE
1 Cross references
232 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSACLG00000008663
Gene Symbol: ACVR2B
3 Cross references
196 Possible Orthologues:

Activin A Receptor Type 2ba

Ensembl ID : ENSACLG00000017251
Gene Symbol: ACVR2BA
1 Cross references
193 Possible Orthologues:

Activin Receptor Type-2b-Like

Ensembl ID : ENSACLG00000017290
Gene Symbol: LOC113029552
3 Cross references
193 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).